Brokerages Set Replimune Group, Inc. (NASDAQ:REPL) PT at $4.88

Replimune Group, Inc. (NASDAQ:REPL) has been given an average rating of “Reduce” by the ten research firms that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating and seven have given a hold rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $4.8750.

A number of research analysts have weighed in on REPL shares. Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Jefferies Financial Group reissued a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Leerink Partners restated a “market perform” rating and issued a $2.00 target price (down from $11.00) on shares of Replimune Group in a report on Monday, April 13th. HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Finally, BMO Capital Markets downgraded Replimune Group from a “market perform” rating to an “underperform” rating in a research note on Monday, April 13th.

Replimune Group Price Performance

Shares of REPL opened at $8.88 on Wednesday. The business’s fifty day moving average is $5.25 and its 200 day moving average is $7.26. Replimune Group has a 12-month low of $1.50 and a 12-month high of $13.24. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The stock has a market cap of $733.22 million, a P/E ratio of -2.58 and a beta of 0.88.

Insider Activity

In related news, insider Christopher Sarchi sold 12,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total transaction of $110,880.00. Following the completion of the sale, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. This represents a 6.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Replimune Group

A number of institutional investors and hedge funds have recently bought and sold shares of REPL. International Assets Investment Management LLC purchased a new stake in Replimune Group in the 4th quarter valued at $29,000. Russell Investments Group Ltd. raised its position in Replimune Group by 3,638.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after buying an additional 7,569 shares during the last quarter. CWM LLC raised its position in Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock valued at $39,000 after buying an additional 2,886 shares during the last quarter. Essential Partners LLC raised its position in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after buying an additional 5,624 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its position in Replimune Group by 99.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock valued at $58,000 after buying an additional 6,873 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.